Similarities and differences of cerebral β-amyloid protein characteristics between 5xFAD transgenic mice and alzheimer's disease patients

doi:10.3969/j.issn.1006-7795.2022.01.018

Abstract

Abstract: Objective To explore the relationship between 5xfad transgenic mice and Alzheimer's disease similarities and differences amyloid β-protein (Aβ) plaque characteristics. Methods Immunofluorescence staining was used to detect Aβ plaques in the brain of 5xFAD transgenic mice and Alzheimer's disease (AD) patients by monoclonal antibody (4G8). The qualitative and quantitative analysis of Aβ plaques in the brain of 5xFAD transgenic mice and AD patients was conducted by CaseViewer software, and the similarities and differences in the morphology, quantity and type of Aβ plaques in the brain of 5xFAD transgenic mice and AD patients were compared Results The main similarities between the characteristics of Aβ plaques in the brain of 5xFAD transgenic mice and AD patients were as follows: obvious Aβ plaques were found in the cerebral cortex and hippocampus of both mice and AD patients; Diffused Aβ plaques and dense Aβ plaques were observed in both of them. The proportion of Aβ plaques with A diameter of <15 μm was the highest in both brain regions. The number of Aβ plaques at [45,60)μm and ≥60 μm in the same brain area was similar between the two groups. Both have obvious cerebral amyloid angiopathy (CAA) in their brains. The main differences in the characteristics of Aβ plaques in the brains of 5xFAD transgenic mice and AD patients were as follows: Aβ plaques with A diameter of <15 μm in the brains of 5xFAD transgenic mice were significantly less than Aβ plaques of the same area in the brains of AD patients (P<0.001); Aβ plaques with diameters of [15,30)μm and [30,45)μm were significantly higher than those with the same area in AD patients (P=0.001, P=0.020); In addition, Aβ plaques with typical coronal structure were observed in the dense Aβ plaques in AD patients, but not in 5xFAD transgenic mice. Conclusion The location, main morphology of Aβ plaques, number of Aβ plaques with diameter of [45,60) μm and ≥60 μm in the same area and characteristics of CAA are highly similar to the AD patient; however, the number of Aβ plaques with a diameter of <15 μm, [15,30)μm and[30,45)μm in the same area of the brain, and the characteristics of Aβ plaque with or without typical coronal structure are different from those of AD patients.

Key words: Alzheimer's disease (AD), β-amyloid protein (Aβ), Aβ plaque, 5xFAD transgenic mice, AD patients

CLC Number:

R743

Meng Xia, Li Meng, Wang Jingjing, Zhang Jing, Chen Baian, Lu Jing. Similarities and differences of cerebral β-amyloid protein characteristics between 5xFAD transgenic mice and alzheimer's disease patients[J]. Journal of Capital Medical University, 2022, 43(1): 106-112.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2022.01.018

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2022/V43/I1/106

References

[1] Nelson P T, Alafuzoff I, Bigio E H, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature[J]. J Neuropathol Exp Neurol, 2012, 71(5): 362-381.
[2] Benilova I, Karran E, De Strooper B. The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes[J]. Nat Neurosci, 2012, 15(3): 349-357.
[3] Ke P C, Zhou R H, Serpell L C, et al. Half a century of amyloids: past, present and future[J]. Chem Soc Rev, 2020, 49(15): 5473-5509.
[4] Selkoe D J. Biology of β-amyloid precursor protein and the mechanism of Alzheimer disease[M] //Terry R D. Alzheimer Disease. Philadelphia: Lippincott Williams & Wilkins, 1999: 293-310.
[5] Haass C, Kaether C, Thinakaran G, et al. Trafficking and proteolytic processing of APP[J]. Cold Spring Harb Perspect Med, 2012, 2(5): a006270.
[6] Braak H, Thal D R, Ghebremedhin E, et al. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years[J]. J Neuropathol Exp Neurol, 2011, 70(11): 960-969.
[7] Revesz T, Ghiso J, Lashley T, et al. Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view[J]. J Neuropathol Exp Neurol, 2003, 62(9): 885-898.
[8] Greenberg S M, Bacskai B J, Hernandez-Guillamon M, et al. Cerebral amyloid angiopathy and Alzheimer disease-one peptide, two pathways[J]. Nat Rev Neurol, 2020, 16(1): 30-42.
[9] Revesz T, Holton J L, Lashley T, et al. Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies[J]. Acta Neuropathol, 2009, 118(1): 115-130.
[10] Oakley H, Cole S L, Logan S, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation[J]. J Neurosci, 2006, 26(40): 10129-10140.
[11] Jawhar S, Trawicka A, Jenneckens C, et al. Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Aβ aggregation in the 5xFAD mouse model of Alzheimer's disease[J]. Neurobiol Aging, 2012, 33(1): 196.e29-196.e40.
[12] Richard B C, Kurdakova A, Baches S, et al. Gene dosage dependent aggravation of the neurological phenotype in the 5xFAD mouse model of Alzheimer's disease[J]. J Alzheimers Dis, 2015, 45(4): 1223-1236.
[13] Giannoni P, Arango-Lievano M, Neves I D, et al. Cerebrovascular pathology during the progression of experimental Alzheimer's disease[J]. Neurobiol Dis, 2016, 88: 107-117.
[14] Wisniewski H M, Bancher C, Barcikowska M, et al. Spectrum of morphological appearance of amyloid deposits in Alzheimer's disease[J]. Acta Neuropathol, 1989, 78(4): 337-347.
[15] Attems J. Sporadic cerebral amyloid angiopathy: pathology, clinical implications, and possible pathomechanisms[J]. Acta Neuropathol, 2005, 110(4): 345-359.
[16] Attems J, Jellinger K A. The overlap between vascular disease and Alzheimer's disease-lessons from pathology[J]. BMC Med, 2014, 12: 206.
[17] Kapasi A, Schneider J A. Vascular contributions to cognitive impairment, clinical Alzheimer's disease, and dementia in older persons[J]. Biochim Biophys Acta, 2016, 1862(5): 878-886.
[18] Vinters H V. Emerging concepts in Alzheimer's disease[J]. Annu Rev Pathol, 2015, 10: 291-319.
[19] Thal D R, Capetillo-Zarate E, Del Tredici K, et al. The development of amyloid beta protein deposits in the aged brain[J]. Sci Aging Knowledge Environ, 2006, 2006(6): re1.
[20] Thal D R, Rüb U, Orantes M, et al. Phases of a beta-deposition in the human brain and its relevance for the development of AD[J]. Neurology, 2002, 58(12): 1791-1800.
[21] Braak H, Thal D R, Ghebremedhin E, et al. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years[J]. J Neuropathol Exp Neurol, 2011, 70(11): 960-969.
[22] Dickson D W. The pathogenesis of senile plaques[J]. J Neuropathol Exp Neurol, 1997, 56(4): 321-339.